Novartis Bets $2B on Next-Gen Allergy Drug to Disarm Immune Cells

PALO ALTO, Calif. – March 27, 2026 – In a bold move signaling a major push into the next generation of allergy treatments, pharmaceutical giant Novartis announced today its intention to acquire Excellergy, a clinical-stage biotechnology company, in a deal potentially worth up to $2 billion.

The acquisition centers on Excellergy's lead candidate, Exl-111, a potentially first-in-class therapy for severe allergic diseases that is just entering early-stage human trials. The deal, which includes upfront and future milestone payments, underscores the immense value being placed on innovative science that promises to move beyond existing treatment paradigms for millions of patients suffering from debilitating allergies.

A New Frontier in Allergy Treatment

For decades, the primary target for severe allergy biologics has been Immunoglobulin E (IgE), the antibody that acts as the central alarm system for allergic reactions. When IgE binds to immune effector cells like mast cells and basophils, it primes them to release a cascade of inflammatory chemicals upon encountering an allergen, leading to symptoms ranging from hives and asthma to life-threatening anaphylaxis.

Novartis is already a major player in this space with Xolair (omalizumab), a blockbuster drug that works by neutralizing free-floating IgE in the bloodstream, preventing it from ever reaching and arming the effector cells. While effective for many, a significant unmet need remains for faster, more profound, and more durable control of allergic diseases.

Excellergy's Exl-111 represents a fundamental evolution of this approach. Described as a trifunctional Effector Cell Response Inhibitor (ECRI), it is designed to attack the allergic cascade from three distinct angles:

1. Neutralizing Free IgE: Like existing therapies, it mops up circulating IgE.
2. Disarming Effector Cells: In its most significant departure from current standards, Exl-111 is engineered to actively pry IgE that is already bound to effector cells off its receptor, effectively disarming cells that are already primed for an attack.
3. Reducing Future Sensitivity: By removing bound IgE, the therapy also triggers a downregulation of the FcεRI receptors on the cell surface, reducing the number of docking sites available for IgE to bind in the future.

This multi-pronged mechanism holds the promise of not just preventing but actively reversing the sensitization of the immune system. “Excellergy adds a differentiated next-generation anti-IgE program that builds on biology Novartis knows well, supported by preclinical evidence and early clinical pharmacokinetic data,” said Fiona Marshall, President of Biomedical Research at Novartis, in a statement. “Exl-111 is designed to go beyond conventional anti-IgE therapy, with the potential to deliver faster and deeper suppression of IgE signaling as well as improved symptom control.”

A Strategic Play in a Heated M&A Market

The staggering potential valuation of up to $2 billion for a company with a lead asset still in Phase 1 development highlights a key trend in the biopharmaceutical industry. With major blockbuster drugs facing patent expirations over the next decade—the so-called “patent cliff”—large pharma companies are aggressively pursuing early-stage, high-potential assets to replenish their pipelines.

The deal represents a massive victory for Excellergy's venture capital backers, including Red Tree Venture Capital, which seeded the company in 2021, and Samsara BioCapital and Decheng Capital, which led a $70 million Series A funding round in late 2025. With a total of just under $80 million raised, the acquisition provides a remarkable return on investment and validates the strategy of funding ambitious, first-in-class science.

For Novartis, the acquisition is a calculated strategic move rather than a speculative gamble. It deepens the company's long-standing expertise in immunology and allergy, building upon the legacy of its successful drug, Xolair. By acquiring Excellergy, Novartis is not just buying a promising molecule; it is attempting to secure a leadership position in the future of the multi-billion dollar allergy market, potentially leapfrogging competitors who are also racing to develop next-generation IgE-targeted therapies.

“This acquisition validates the transformative potential of our ECRIs and the hard work of the entire Excellergy team,” said Todd Zavodnick, Chief Executive Officer of Excellergy. “Novartis brings world-class global development capabilities and a proven track record of bringing novel medicines to patients.”

The Clinical Path Forward

All eyes will now turn to the clinical development of Exl-111. The drug is currently being evaluated in the Phase 1 DISARM trial, a randomized, double-blind, placebo-controlled study that began dosing its first subjects in February 2026. The trial is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of the drug.

While human data is in its infancy, the preclinical results were highly compelling. Studies showed that Exl-111 could rapidly dissociate over 99% of IgE from its receptors on basophils and induce a profound reduction of nearly 95% in the expression of those receptors on the cell surface. These results, combined with early pharmacokinetic data from the Phase 1 trial suggesting sustained drug exposure, form the scientific bedrock of the acquisition's high valuation.

Given its novel mechanism and potential to offer a substantial improvement over available therapies, Exl-111 could be a candidate for expedited regulatory pathways such as the FDA's Breakthrough Therapy Designation. Such a designation would accelerate its development and review, potentially bringing this innovative treatment to patients sooner.

Under the stewardship of Novartis, with its vast resources and deep experience in clinical development and commercialization, Exl-111 is now positioned to be advanced rapidly through the necessary clinical trials. If successful, the acquisition could mark a pivotal moment, heralding a new era of more effective and comprehensive treatments for those burdened by severe IgE-mediated diseases.